Last Updated: May 10, 2026

Profile for Argentina Patent: 090126


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 090126

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
9,089,489 Feb 18, 2033 Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride
9,375,404 Feb 18, 2033 Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride
9,937,132 Feb 18, 2033 Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Key insights for pharmaceutical patentability - Argentina patent AR090126

Last updated: April 25, 2026

What Is AR090126 in Argentina, and How Broad Are Its Patent Claims?

What does AR090126 cover?

AR090126 is an Argentine patent publication tied to pharmaceutical subject matter, filed and published in the Argentine IP system. The available dataset for AR090126 in this workspace does not include the full claim set, independent claim language, specification summary, or country-specific legal status needed to map:

  • claim scope (by therapeutic use, compound class, formulation, polymorph, salt, and method of treatment),
  • dependency structure (Markush breadth vs narrow dependent claims),
  • claim-to-claim fallback positions (how coverage changes with amendments),
  • or how the claims interlock with other patents in Argentina for the same product.

Because the core claim text and bibliographic/legal records for AR090126 are not present here, a complete, accurate “scope and claims” analysis cannot be produced.

What is the claim scope and where are the boundaries?

A correct scope analysis requires the exact wording of:

  • independent claims (compound, composition, method of treatment, and/or second medical use),
  • dependent claims (specific embodiments),
  • claim construction anchors (definitions of “compound of formula,” “pharmaceutical composition,” “therapeutically effective amount,” assay/IC50 thresholds, and required structural features),
  • and any claim limitations tied to examples, preferred embodiments, or working examples.

Those elements are not included in the provided information set for AR090126 in this workspace, so any attempt to infer scope would risk inventing claim language or coverage boundaries.

What does the Argentine patent landscape look like around AR090126?

Landscape mapping for AR090126 requires, at minimum:

  • identification of the drug/product identity behind AR090126,
  • linked patents in Argentina by:
    • same priority family,
    • continuation/divisional family equivalents,
    • salt/polymorph/formulation filings,
    • method-of-treatment and dosing regimen filings,
    • and any related process patents that affect manufacturing freedom-to-operate.
  • status signals:
    • granted vs pending,
    • oppositions (if any),
    • term status and any patent term adjustments,
    • and whether any claims are limited by prosecution or amendment.

This workspace does not include those bibliographic links, family mappings, or the Argentine legal status for AR090126, so a landscape view cannot be made without fabricating connections.

How does claim scope typically impact Argentina freedom-to-operate?

A proper FTO impact assessment must connect AR090126’s claims to a specific product and specific Argentine counterparts. Without the claim set and product identity, there is no reliable way to assess whether infringement hinges on:

  • molecular identity (exact structure vs generic formula),
  • salt/form polymorph coverage,
  • formulation excipients and dosage form,
  • therapeutic method endpoints,
  • or dosing regimen language.

No accurate infringement pathways can be derived from missing claim text and missing product identification.


What decisions can investors or R&D teams make from AR090126?

None can be made from the information present here without a claim set, publication family mapping, and legal status. Any decision guidance would depend on invented details.


Key Takeaways

  • AR090126: a relevant Argentine pharmaceutical patent identifier.
  • Claim scope analysis: cannot be completed because the claim text and claim structure are not available in this workspace.
  • Argentina patent landscape: cannot be mapped because the drug identity, family equivalents, and legal status records are not available here.

FAQs

1) Is AR090126 a compound patent, formulation patent, or method-of-use patent?

Cannot be determined from the available information in this workspace because the claim set and specification excerpts are not included.

2) Does AR090126 include claims for salts, polymorphs, or specific formulations?

Not determinable without the dependent claim language and claim definitions.

3) What is the priority date and filing/publication timeline for AR090126?

Not provided in the available dataset here.

4) Is AR090126 granted, pending, or lapsed in Argentina?

Not provided in the available dataset here.

5) Which other Argentine patents are in the same family as AR090126?

Not provided in the available dataset here.


References

[1] (No citable sources are available in this workspace that contain AR090126 bibliographic records or the claim text.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.